Answers are grounded in this paper and cite their sources.
In vitro analysis reveals gentiana lutea reduces mycotoxin cytotoxicity in intestinal cells, suggesting health benefits.
Objective We investigated the phytochemical composition, gastrointestinal bioaccessibility, and protective effects against mycotoxin-induced toxicity of Gentiana lutea L. flower, a botanical species traditionally used in European herbal medicine. Methods Gentiana lutea flower samples were collected from the Majella National Park and chemically characterized using HPLC-PDA and NMR metabolomics, revealing the presence of abundant bioactive compounds (iridoids, secoiridoids, and xanthones), as well as quantifying the levels of amino acids, organic acids, and sugars. Following in vitro gastrointestinal digestion, bioaccessible fractions were analyzed and subjected to transepithelial transport assays using differentiated Caco-2 monolayers. Results Gene expression analysis and cytotoxicity evaluation on Caco-2 cell cultures demonstrated that digested Gentiana significantly mitigated the toxic effects of aflatoxin B1 (AFB1), ochratoxin A (OTA), and beauvericin (BEA). The digested Gentiana samples reduced the expression of pro-apoptotic genes (BAX, CASP3), preserved intestinal barrier integrity by modulating tight junction-related genes (CL-2, ZO-1), and promoted antioxidant responses through SRXN1 regulation. Conclusion These findings highlight the potential of Gentiana lutea flowers as a source of functional phytocompounds for intestinal barrier protection against mycotoxins.
No takes yet. Share an insight, caveat, or question.
Matteo et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: